Study on the Effectiveness and Safety of Pirtobrutinib and Rituximab for Untreated Adult Patients with Indolent Mantle Cell Lymphoma

2 1 1 1

What is this study about?

This clinical trial is focused on studying a type of cancer called Mantle Cell Lymphoma (MCL), which is a form of non-Hodgkin’s lymphoma. The study is specifically looking at patients with a less aggressive form of this disease, known as indolent MCL, who have not yet received any treatment. The trial will test the effectiveness and safety of a new treatment combination using two medications: pirtobrutinib and rituximab. Pirtobrutinib, also known by its code names LOXO-305 and LY3527727, is taken orally in the form of film-coated tablets. Rituximab is given as an intravenous infusion, which means it is administered directly into the bloodstream through a vein.

The purpose of the study is to see if this combination of pirtobrutinib and rituximab can be a good alternative to the usual treatments for MCL, which often involve a mix of chemotherapy and immunotherapy. The study will follow participants over a period of time to monitor how well the treatment works and to check for any side effects. Participants will receive the treatment and be observed for changes in their condition, with regular assessments to track their progress. The study aims to provide valuable information on whether this new combination can help manage the disease more effectively than current standard treatments.

Throughout the study, researchers will collect data on how the treatment affects the cancer and the overall health of the participants. This includes looking at the rate of complete remission, which means the cancer is no longer detectable, and monitoring any adverse effects that may occur. The study will also evaluate the quality of life of participants using questionnaires designed to measure well-being and daily functioning. By the end of the study, the goal is to have a clearer understanding of the potential benefits and risks of using pirtobrutinib and rituximab together for treating indolent MCL.

1 joining the study

Upon joining the study, the patient will be required to provide written informed consent. This consent confirms understanding and agreement to comply with the study’s requirements and restrictions.

2 initial assessments

Initial assessments will be conducted to confirm eligibility. These assessments include a review of medical history, physical examination, and laboratory tests to ensure the patient meets the study criteria.

3 treatment initiation

The treatment involves a combination of two medications: pirtobrutinib and rituximab. Pirtobrutinib is administered orally in the form of Jaypirca 100 mg film-coated tablets. The dosage and frequency will be determined by the study protocol.

Rituximab is administered through an intravenous infusion. The specific dosage and schedule will be provided by the healthcare team.

4 treatment cycles

The treatment is organized into cycles. Each cycle includes the administration of the medications as per the study protocol. The primary objective is to assess the complete remission rate by the end of Cycle 6.

5 monitoring and assessments

Throughout the study, regular monitoring and assessments will be conducted. These include evaluating the effectiveness of the treatment and monitoring for any adverse events. The patient’s quality of life will also be assessed using specific questionnaires.

6 end of treatment

At the end of the treatment period, a final assessment will be conducted to evaluate the overall response to the treatment. This includes a review of the patient’s health status and any changes in the condition.

7 follow-up

After completing the treatment, follow-up visits will be scheduled to monitor the patient’s long-term health and any potential late effects of the treatment.

Who Can Join the Study?

Must be an adult (18 years or older).
Must have a stable disease without signs of getting worse for at least 3 months.
Women who can have children must have a negative pregnancy test and agree to use very effective birth control during the study and for a certain time after.
Men must use very effective birth control if they are sexually active with a woman who can have children, during the study and for a certain time after.
Must be willing and able to sign a consent form agreeing to follow the study rules.
Cannot be part of another clinical trial or have taken an experimental drug for a different condition in the past 2 years.
Must have a confirmed diagnosis of Mantle Cell Lymphoma (MCL) according to specific medical classifications.
Must not have received any prior treatment for MCL, except for a diagnostic procedure called splenectomy.
Must not have symptoms related to MCL.
Must have an ECOG performance status of less than 2, which means being fully active or having some symptoms but still able to carry out light work.
Must be in clinical stage I-IV according to the Ann Arbor classification without symptoms caused by MCL.
Patients with a type of MCL that mainly affects the bone marrow or blood are eligible, as long as they have a low tumor burden.
Must meet certain laboratory test values at screening, including:
- Neutrophil count of at least 1×10⁹/L
- Hemoglobin level of at least 100 g/L
- Platelet count of at least 100×10⁹/L
- Liver enzymes (AST and ALT) not more than 3 times the upper limit of normal (ULN)
- Total bilirubin not more than 1.5 times ULN, unless due to a condition called Gilbert’s disease
- Creatinine clearance of at least 30 ml/min, which measures kidney function
- Normal blood clotting ability, with specific test values not greater than 1.5 times ULN

Who Cannot Join the Study?

Patients who have already received treatment for their condition cannot participate.
Patients with a type of MCL that is not considered indolent (a slow-growing form of the disease) are not eligible.
Patients who are part of a vulnerable population (groups that may need special protection or care) are not eligible.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country
Hospital Universitario Y Politecnico La Fe	Valencia	Spain
Hospital Universitario De Salamanca	Salamanca	Spain
Hospital Universitario De Navarra	Pamplona	Spain
Unidade Local De Saúde De Santa Maria, E.P.E.	Lisbon	Portugal

Other Sites

Site Name	City	Country
Hospital General Universitario Gregorio Maranon	Madrid	Spain
Hospital Universitario 12 De Octubre	Madrid	Spain
Hestia Duran I Reynals	L'hospitalet De Llobregat	Spain
Hospital Clinic De Barcelona	Barcelona	Spain
Instituto Portugues De Oncologia De Lisboa Francisco Gentil E.P.E.	Lisbon	Portugal
University Clinical Hospital Virgen De La Arrixaca	Murcia	Spain
Hospital Costa del Sol	Marbella	Spain
Hqnrgpxp Uuvofqmwhowft Hpsjpmnt Telxs y Pgmmux Ixekrfxm Cpdpvt dpkynjvzjvutyjrys (jxat	Badalona	Spain
Hbwxxcjy Vyzo dfupjfzh	Barcelona	Spain

Trial status

Country	Status	Recruitment Start
Portugal	Recruiting	28.03.2025
Spain	Recruiting	28.03.2025

Trial locations

Investigated drugs:

Pirtobrutinib is a medication being studied for its potential to help treat a type of cancer called Mantle Cell Lymphoma, which is a slow-growing form of cancer that affects the lymph nodes. This medication works by blocking certain proteins in the body that help cancer cells grow and survive. By stopping these proteins, pirtobrutinib may help to slow down or stop the growth of cancer cells.

Rituximab is a medication that is used to treat certain types of cancer, including Mantle Cell Lymphoma. It is a type of therapy known as a monoclonal antibody, which means it is designed to target and attach to specific proteins on the surface of cancer cells. By doing this, rituximab helps the body’s immune system to recognize and destroy these cancer cells. In this trial, rituximab is being used in combination with pirtobrutinib to see if the two medications together can be more effective in treating the cancer than other standard treatments.

Investigated diseases:

Mantle cell lymphoma

Mantle Cell Lymphoma – Mantle Cell Lymphoma (MCL) is a type of non-Hodgkin lymphoma that originates from B-cells, a type of white blood cell. It is characterized by the overproduction of abnormal B-cells that accumulate in the lymph nodes, spleen, bone marrow, and sometimes the gastrointestinal tract. The disease typically progresses slowly, but it can become more aggressive over time. Patients may experience symptoms such as swollen lymph nodes, fatigue, fever, night sweats, and weight loss. As the disease advances, it can lead to complications due to the impaired function of affected organs. MCL is considered indolent when it progresses at a slower rate and may not immediately require aggressive treatment.

Trial ID:

2024-511983-97-00

Protocol code:

IMCL-2023

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on the Effectiveness and Safety of Pirtobrutinib and Rituximab for Untreated Adult Patients with Indolent Mantle Cell Lymphoma

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?